AI-Driven Risk Prediction Tool (TSP-9) Informs Risk-Aligned Care for Patients with Barrett’s Esophagus

TL;DR

A new AI tool called TSP-9 helps doctors assess which Barrett’s esophagus patients are most likely to develop cancer, enabling personalized care.

Contribution

The novel contribution is the development and real-world application of TSP-9, an AI-driven risk prediction tool for Barrett’s esophagus progression.

Findings

TSP-9 successfully stratified risk in three low-risk Barrett’s esophagus patients.

The tool provides personalized risk assessments for progression to high-grade dysplasia or cancer.

AI-powered tools like TSP-9 are expected to become standard in gastroenterology.

Abstract

Background and Clinical Significance: Barrett’s esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Accurately predicting which patients with BE are at the highest risk of progressing to EAC is a significant clinical challenge. This article discusses how the tissue systems pathology test (TSP-9, TissueCypher) can help guide risk-aligned care for patients with BE. TSP-9 is an AI-driven prognostic test that stratifies patients with BE for risk of progression to high-grade dysplasia (HGD)/EAC. Case Report Presentation: Three clinically low-risk patients had esophageal biopsies tested by TSP-9. The real-world utility of TSP-9 is demonstrated through a brief discussion of how the test was utilized to assess each patient’s personalized risk of BE progression to HGD/EAC and inform risk-aligned care. Conclusions: The use of validated AI-powered tools such as TSP-9 is poised to become standard practice in gastroenterology clinical settings and will help improve health outcomes for patients with BE to prevent EAC-related mortality.

Figures